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Treatment outcomes using the standard regimen (a macrolide, ethambutol, and
rifampicin) for Mycobacterium avium complex-pulmonary disease (MAC-PD) remain
unsatisfactory. Thus, improved treatment regimens for MAC-PD are required.
Clofazimine has recently been revisited as an effective drug against mycobacterial
infection. We performed a comparison between the standard regimen and an alternative
regimen (replacing the rifampicin of the standard regimen with clofazimine) based
on the intracellular anti-MAC activities of the individual drugs in a murine model of
chronic progressive MAC-pulmonary infection (MAC-PI). The intracellular anti-MAC
activities of the individual drugs and their combinations in murine bone marrow-derived
macrophages (BMDMs) were determined. The treatment efficacies of the standard
and clofazimine-containing regimens were evaluated in mice chronically infected with
M. avium by initiating 2- and 4-week treatment at 8 weeks post-infection. Bacterial loads
in the lung, spleen, and liver were assessed along with lung inflammation. Insufficient
intracellular anti-MAC activity of rifampicin in BMDMs was recorded despite its low
in vitro minimum inhibitory concentrations (MICs), whereas optimal intracellular killing
activity against all tested MAC strains was achieved with clofazimine. Compared to
the standard regimen, the clofazimine-containing regimen significantly reduced CFUs
in all organs and achieved marked reductions in lung inflammation. The replacement of
rifampicin with clofazimine in the treatment regimen resulted in more favorable outcomes
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in an animal model of chronic progressive MAC-PI. Intriguingly, 2 weeks of treatment
with the clofazimine-containing regimen reduced bacterial loads more effectively than
4 weeks of treatment with the standard regimen in M. avium-infected mice. Thus, the
clofazimine-containing regimen also had a treatment-shortening effect.
Keywords: Mycobacterium avium complex-pulmonary disease, clofazimine, clofazimine-containing regimen,
standard treatment regimen, minimum inhibitory concentrations, intracellular drug susceptibility test, in vivo drug
susceptibility test, chronic progressive murine model
INTRODUCTION
Non-tuberculous mycobacteria (NTM), which are ubiquitous
and opportunistic pathogens, comprise all the members of
Mycobacterium except the Mycobacterium tuberculosis complex
and Mycobacterium leprae (Baldwin et al., 2019; Daley et al.,
2020). The incidence and prevalence of infectious disease caused
by NTM have been increasing globally, leading to an emerging
problem related to the difficulty of treatment (Loebinger, 2017;
Lee et al., 2019).
The Mycobacterium avium complex (MAC), which comprises
slow-growing Mycobacterium species, has been ranked as the
most common group of NTM pathogens worldwide (Hoefsloot
et al., 2013; Daley et al., 2020). In particular, M. avium
and Mycobacterium intracellulare are the main species causing
pulmonary disease (PD) and include two major forms: nodular
bronchiectatic and fibrocavitary (Koh, 2017). Patients with drug-
susceptible MAC-PD generally receive at least three antibiotics, a
macrolide [azithromycin or clarithromycin (CLR)], ethambutol
(EMB), and rifampicin (RIF), as a standard regimen for at least
12 months based on previous empirical clinical investigations
(Griffith et al., 1996; Wallace et al., 1996; Wallace et al.,
2014; Griffith, 2018). Although the clinical effectiveness of EMB
and RIF in MAC-PD treatment has not been fully verified,
these drugs are used as supportive treatments to prevent
microbiological resistance to macrolide monotherapy (Kim et al.,
2019). In addition, the minimum inhibitory concentrations
(MICs) of EMB and RIF are associated with treatment efficacy,
and 85.3% of patients whose MAC isolates have MICs of
<8 mg/L for RIF and/or EMB have successful treatment
(Kwon et al., 2018).
However, the serum concentrations of macrolides, the key
drugs for the treatment of MAC disease, have been reported
to be low because of the interplay with RIF (Koh et al., 2012;
Shimomura et al., 2015; Jeong et al., 2016). RIF is a potent
inducer of cytochrome P450 (CYP3A) enzymatic activity, and
macrolides are CYP3A inhibitors. However, due to the prominent
effect of RIF-mediated CYP3A activation, coadministration of
RIF and a macrolide may lead to poor treatment outcomes
(Shimomura et al., 2015; Akiyama et al., 2019). Moreover,
increased serum concentrations of RIF can cause side effects, such
as liver damage, leukopenia, and thrombocytopenia (Shimomura
et al., 2015). In addition, a previous study revealed that a
treatment regimen consisting only of a macrolide and EMB
without RIF resulted in non-inferior outcomes compared with
those of the standard three-drug regimen in selected cases
(Miwa et al., 2014). Furthermore, Jarand et al. (2016) reported
that patients treated with a macrolide, EMB, and clofazimine
(CFZ) instead of RIF showed better treatment outcomes than
those treated with a RIF-containing regimen. All these results
have raised the question of whether RIF plays a sufficient role
in MAC therapy despite the low in vitro MIC value of RIF
against MAC strains.
CFZ has been used mainly to treat drug-resistant tuberculosis
and leprosy (Tyagi et al., 2015). Moreover, it has been introduced
for the treatment of NTM-PD caused by not only MAC but
also Mycobacterium abscessus (MAB), with promising results
(Roussel and Igual, 1998; Field and Cowie, 2003; Jarand et al.,
2016; Yang et al., 2017). Particularly, in the treatment of MAC-
PD, the CFZ-containing regimen showed favorable treatment
outcomes in treatment-naïve patients as well as those with
refractory disease (Jarand et al., 2016; Martiniano et al., 2017). In
addition, under the guidelines from the Clinical and Laboratory
Standards Institute, interest in combinatory regimens containing
CFZ has re-emerged, even for the treatment of macrolide-
resistant MAC infections (CLSI, 2018). Notably, CFZ had a
bacteriostatic effect, and its use in combination with CLR had a
synergistic ability to prevent regrowth of MAB and MAC in vitro
(Ferro et al., 2016).
However, the clinical use of CFZ based on drug susceptibility
testing (DST) still lacks sufficient evidence due to the unclear
and unreliable breakpoint for CFZ susceptibility testing (Huang
et al., 2018; Luo et al., 2018). Additionally, correlations between
the results from in vitro DST, intracellular activity, and in vivo
treatment outcomes have not been clearly investigated for MAC
clinical isolates (Huang et al., 2018). Although a synergistic
effect of CLR with CFZ was demonstrated in a murine model
of M. avium ATCC 700898 infection (Lanoix et al., 2020), our
present study, to the best of our knowledge, is the first to evaluate
CFZ activity against a chronic and progressive infection in a
murine model that reflects the clinical situation, along with an
investigation of its intracellular anti-MAC activity. Generally,
MAC-PD treatment is initiated once disease progression is noted
radiologically or once symptoms worsen in patients who have
chronic MAC lung infection, with significant bacterial loads
and severe inflammation (Thomson and Yew, 2009). Thus,
the establishment of chronic MAC-PI in animal models to
mimic the condition of patients is necessary to rationally devise
more effective MAC-PD chemotherapy regimens. However, the
main limitation of in vivo studies is that chronic infection
with MAC strains via aerosolization is not easily achieved
in mice. Accordingly, the majority of experimental studies
of MAC infection in vivo have employed intraperitoneal,
intratracheal or intranasal injection rather than aerosol infection
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(Amaral et al., 2011; Bruffaerts et al., 2017; Abdissa et al., 2018;
Kannan et al., 2019). Our previous study mimicked chronic
infection with different MAC strains via aerosolization to
investigate the possibility of reactivation of MAC infection, and
it revealed that the different MAC strains in the mice exhibited
different growth rates, which might be associated with differences
in host-pathogen interactions (Cha et al., 2015).
In the present study, to compare efficacy between these
regimens in MAC-infected mice, we used M. avium SMC #7,
a clinical isolate, to cause a chronic progressive pulmonary
infection (PI) in mice. The main purpose of this study was to
evaluate the efficacy of the standard regimen and an alternative
regimen that replaced RIF with CFZ in a murine model of chronic
progressive MAC infection based on the in vitro and intracellular
activities of individual drugs against MAC clinical isolates.
MATERIALS AND METHODS
Mycobacterial Strains and Culture
Conditions
Eight Mycobacterium species were used in this study (Table 1).
Briefly, reference strains were obtained from the American Type
Culture Collection (ATCC; Manassas, VA, United States), and
all clinical isolates were obtained from patients with the typical
nodular bronchiectatic form of MAC-PD who had never been
exposed to antimycobacterial antibiotics at the time of diagnosis
(Samsung Medical Center, SMC; Seoul, South Korea). All strains
were cultivated in Middlebrook 7H9 broth (BD-Difco, Pont-
de-Claix, France) supplemented with 10% oleic acid-albumin-
dextrose-catalase (OADC) at 37◦C. Single-cell suspensions of
each strain were prepared as previously described (Cha et al.,
2015), and colony-forming units (CFUs) were determined on
Middlebrook 7H10 agar plates (BD-Difco).
Antibiotics
All drugs (CLR, EMB, RIF, and CFZ) were purchased from
Sigma-Aldrich, Inc. (St. Louis, MO, United States) and
were diluted in Dulbecco’s phosphate-buffered saline (DPBS;
Biowest, Nuaillé, France) after complete dissolution in dimethyl
sulfoxide for in vitro DST and intracellular activity testing. For
in vivo oral administration, 0.5% carboxymethylcellulose was
used as a vehicle.
Ethics and the Animal Model
Specific pathogen-free female BALB/c and C57BL/6 (6–
8 weeks of age) mice were purchased from Japan SLC, Inc.
(Shijuoka, Japan). All animal experiments were conducted in
accordance with the Korean Food and Drug Administration
(KFDA) guidelines and approved by the Ethics Committee
and Institutional Animal Care and Use Committee of the
Laboratory Animal Research Center at Yonsei University College
of Medicine (Permit Number: 2015-0273 and 2018-0229).
In vitro Susceptibility Testing
In vitro susceptibility testing of MAC strains to individual drugs
was determined by the broth microdilution resazurin assay after
TABLE 1 | Minimum inhibitory concentrations (MICs) of anti-mycobacterial drugs
against Mycobacterium strains used in this study.
MIC (mg/L)
Species Strains CLR EMB RIF CFZ
M. avium
CP000479.1* 1 8 4 2
ATCC 700898* 0.5 8 1 4
SMC #1 0.5 4 0.5 4
SMC #7 0.5 8 4 2
M. intracellulare
ATCC 13950* 0.25 4 0.25 2
SMC #8 0.5 4 2 4
SMC #11 1 1 0.5 1
M. tuberculosis
ATCC 27294* N.D. 2 0.25 0.25
CLR, clarithromycin; EMB, ethambutol; RIF, rifampicin; CFZ, clofazimine; SMC,
Samsung Medical Center (Seoul, South Korea); N.D., not determined.
*These strains were used as controls for the relevant experiments in this study.
7 days of incubation, as previously described. The MICs of the
drugs were defined as the lowest concentration of the agents
that inhibited bacterial growth. All MIC results for the tested
MAC strains were verified by conducting each test twice (in
duplicate wells).
Intracellular Anti-MAC Activities of
Individual Drugs and Their Combinations
Murine bone marrow-derived macrophages (BMDMs) from
BALB/c and C57BL/6 mice were differentiated in Dulbecco’s
modified Eagle’s medium (Biowest) supplemented with 10% fetal
bovine serum (Biowest) and 10% L929 supernatant as previously
described (Choi et al., 2019) and used for intracellular anti-MAC
activities of the tested drugs at the indicated concentrations.
Briefly, BMDMs (3 × 105 cells/ml) were cultured in a 48-well
plate for 24 h, infected with the indicated MAC strains (Table 1)
at multiplicity of infection of 3 for 4 h, and washed with DPBS.
The cells were then cultured with or without drugs in duplicate
or triplicate wells for 72 h. The cells were then lysed with 0.05%
Triton X-100, and the lysates were serially diluted with DPBS and
spotted a maximum of four times per well on 7H10 agar plates
supplemented with 10% OADC to quantify the numbers of viable
bacteria. Colonies were counted after 14 days of incubation at
37◦C, and the values are reported as the mean CFUs ± standard
deviations per ml of BMDMs. Each experiment was repeated at
least twice independently.
Head-to-Head Assessment of Treatment
Efficacy Between Standard and
CFZ-Containing Regimens in an Animal
Model of Chronic Progressive M. avium
Pulmonary Infection
For in vivo experiments, a total of 44 BALB/c mice were infected
with M. avium SMC #7 via aerosolization as previously described
(Cha et al., 2015). Briefly, the mice were exposed to M. avium
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SMC #7 via aerosolization using an inhalation exposure system
(Glas-Col, Terre Haute, IN, United States). Four to five mice
per group were euthanized at 0, 2, 4, and 8 weeks for the
establishment phase of the infection, two and four mice in the
control group were euthanized at 10 weeks and 12 weeks post
infection, and every five mice in the standard regimen group
and CFZ-containing regimen group were euthanized at 10 and
12 weeks for evaluation of the bacterial loads in the lung, spleen
and liver and histopathological analysis of the lung. At 8 weeks
post-infection, treatment with each regimen 5 days per week for
2 and 4 weeks was initiated by oral gavage. The drug doses were
as follows: 100 mg/kg for CLR and EMB, 10 mg/kg for RIF and
20 mg/kg for CFZ.
Organ homogenates were plated through serial dilution
onto 7H10 agar plates supplemented with 10% OADC and
0.5% amphotericin B (Sigma-Aldrich) for CFU determination.
Bacterial colonies were counted after incubation at 37◦C for
2 weeks. For histopathological analysis, the right superior
lobes of the lungs were preserved in 10% neutral buffered
formalin, embedded in paraffin and sectioned at 4–5 µm,
followed by hematoxylin and eosin staining. The extent of the
affected inflamed area in the lungs was analyzed using open-
source ImageJ software (National Institutes of Health, Bethesda,
MD, United States).
Statistical Analysis
The Mann–Whitney test was used to evaluate differences between
two groups, and ANOVA corrected with Tukey’s test was used
to evaluate differences among multiple groups using GraphPad
Prism version 7 (San Diego, CA, United States). A p-value < 0.05
was considered statistically significant.
RESULTS
Determination of the in vitro MIC Values
and Intracellular Anti-MAC Activities of
Individual Antibiotics
The MICs of CLR, EMB, RIF, and CFZ for the MAC strains
used in this study are given in Table 1. Overall, the MAC strains
were susceptible to CLR according to Clinical and Laboratory
Standards Institute breakpoints (CLSI, 2018) but exhibited
varying susceptibility to EMB, RIF, and CFZ, as previously
reported (Huang et al., 2018; Wetzstein et al., 2020).
Next, we evaluated the intracellular activities of first-line
antibiotics to determine whether a high dose of each drug
is effective in inhibiting MAC growth inside macrophages.
BMDMs from BALB/c mice were infected with M. avium
ATCC 700898 and treated with 10 mg/L CLR, EMB, and RIF
for 3 days (Figure 1A). Interestingly, a low MIC (1 mg/L)
value was observed for RIF in vitro (Table 1), but RIF was
insufficiently effective against M. avium ATCC 700898 at even a
10-fold higher concentration (10 mg/L) in BMDMs (Figure 1A).
Furthermore, ineffective intracellular activity of RIF against
M. intracellulare ATCC 13950 and M. avium SMC #7 in BMDMs
were confirmed despite its low in vitro MICs (0.25 and 4 mg/L,
respectively), whereas significant intracellular activity of RIF
against M. tuberculosis ATCC 27294 was observed at only
1 mg/L (Figures 1B,C). In addition, M. avium ATCC 700898-
infected BMDMs were treated with various concentrations of
first-line antibiotics. The results revealed that compared to
control treatment, RIF alone had no anti-MAC activity at
any concentration in BMDMs (Figure 1D and Supplementary
Figure 1). Similarly, M. intracellulare ATCC 13950 exhibited
tolerance to high RIF concentrations, even at 40 mg/L, in
BMDMs (Figure 1E). Next, to investigate whether the lack
of intracellular anti-MAC activity of RIF was due to specific
characteristics of macrophages from BALB/c mice, BMDMs
from C57BL/6 mice were infected with M. avium ATCC
700898, M. avium 104 (CP000479.1) and M. intracellulare
ATCC 13950 and treated with 10 mg/L RIF. Interestingly,
RIF was again ineffective against those MAC strains, which
was similar to the results obtained for BMDMs from BALB/c
mice (Supplementary Figure 2A). Similar to M. avium ATCC
700898, M. avium 104 (CP000479.1) was inhibited by CLR
concentrations over 10 mg/L but tolerated a high concentration
of RIF (Supplementary Figures 2B,C). Taken together, these
results show that the relatively low or absent intracellular anti-
MAC activity of RIF did not result from its concentration or
specific characteristics of different types of BMDMs, indicating
the existence of inconsistent results between in vitro and
intracellular activities.
Intracellular Anti-MAC Activity of CFZ
To investigate the intracellular anti-MAC activity of CFZ in
BMDMs, BMDMs were infected with M. avium ATCC 700898
and M. intracellulare ATCC 13950 and treated with different
concentrations of CFZ (Figures 2A,B). Concentrations of CFZ
over 5 mg/L exhibited significant intracellular activity against
both strains at 72 h post-infection in BMDMs despite the
relatively high MIC values for M. avium ATCC 700898 and
M. intracellulare ATCC 13950 compared to those for RIF and
CLR (Figure 2A,B). Next, BMDMs were infected with M. avium
ATCC 700898, M. intracellulare ATCC 13950 or M. avium
SMC #7 and treated with 5 mg/L CFZ or 10 mg/L CLR,
and intracellular activity was assessed at 72 h post-infection
(Figure 2C). Remarkably, CFZ inhibited intracellular bacterial
growth to a similar extent as CLR.
Comparison of Anti-MAC Activities
Between the Standard and
CFZ-Containing Regimens in
Macrophages
We next investigated the intracellular anti-MAC activities of
each drug at different concentrations based on the in vitro
MICs in BMDMs (Supplementary Figure 3). According to
the in vitro MIC results (Table 1), the concentrations of all
drugs except CFZ for monotherapy were fixed at 5 × MIC,
and CFZ was fixed at 2 × MIC. The concentrations for the
combined therapy were chosen to be 1 × MIC and 3 × MIC
for each strain. CFZ exhibited an equally significant reduction
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FIGURE 1 | Intracellular anti-MAC activities of first-line drugs in MAC-infected BMDMs. (A) BMDMs were infected with M. avium ATCC 700898 and treated with the
indicated doses of CLR, EMB, and RIF. Unless otherwise indicated, all experiments investigating the intracellular activities of drugs in BMDMs were evaluated at 72 h
post-infection by plating serially diluted cell lysates onto 7H10-OADC agar plates. (B) BMDMs were infected with M. intracellulare ATCC 13950 or M. avium SMC #7
and treated with 10 mg/L RIF. (C) BMDMs were infected with M. tuberculosis H37Rv and treated with 1 mg/L RIF as a control experiment. BMDMs were infected
with (D) M. avium ATCC 700898 or (E) M. intracellulare ATCC 13950 and treated with the indicated doses of RIF. Each experiment was repeated at least twice
independently with duplicate or triplicate wells; the results of a representative experiment are shown. Each dot represents the mean value ± S.D. of duplicate or
triplicate wells, with four spots applied per well. The Mann–Whitney test was used to evaluate significance, and the results are represented as the mean value ± S.D.
***p < 0.001 vs. Pre-Tx. Pre-Tx, pre-treatment; CTL, untreated control.
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FIGURE 2 | Concentration-dependent intracellular activities of CFZ in MAC-infected BMDMs. BMDMs were infected with (A) M. avium ATCC 700898 or
(B) M. intracellulare ATCC 13950 and treated with the indicated dose of CFZ. (C) BMDMs were infected with M. avium ATCC 700898, M. intracellulare ATCC 13950
or M. avium SMC #7 and treated with 5 mg/L CFZ or 10 mg/L CLR. After 72 h of cultivation, bacterial CFUs were enumerated by plating serially diluted cell lysates
on 7H10-OADC agar plates. Each experiment was repeated at least twice independently with triplicate wells; the results of a representative experiment are shown.
Each dot represents the mean value ± S.D. of duplicate or triplicate wells, with four spots applied per well. The Mann–Whitney test was used to evaluate
significance, and the results are represented as the mean value ± S.D. ***p < 0.001 vs. Pre-Tx. Pre-Tx, pre-treatment; CTL, untreated control; hpi, h post-infection.
in the viability of six MAC strains in BMDMs at 72 h post-
infection (p < 0.001), even at only 2 × MIC. Finally, the
intracellular anti-MAC activities of the standard regimen (CLR-
EMB-RIF) versus the CFZ-containing regimen, as shown in
Figure 3 and Supplementary Figure 4, were compared. The
majority of MAC strains (i.e., all strains except M. avium SMC
#7) displayed significantly lower viability at both 1 × MIC
and 3 × MIC for the CFZ-containing regimen than for the
standard regimen at 72 h in BMDMs (p < 0.001) (Figure 3
and Supplementary Figure 4). Interestingly, bacterial growth of
M. intracellulare SMC #11 was naturally inhibited in BMDMs
without anti-MAC drugs. However, we confirmed that it was not
due to cytotoxic effect of M. intracellulare SMC #11 on BMDMs
(data not shown). Taken together, these results suggest that a
concentration of 1 × MIC was sufficient to control intracellular
growth (Figure 3).
Head-to-Head Comparison of Treatment
Efficacy Between the Standard and
CFZ-Containing Regimens in a Murine
Model of Chronic Progressive MAC-PI
Since treatment for patients with MAC-PD is initiated after
disease progression becomes imminent, we established a murine
model of chronic progressive MAC-PI using BALB/c mice by
aerosol infection with M. avium SMC #7 (Figure 4A). At 8 weeks
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FIGURE 3 | Comparative evaluation of the intracellular activities of drug combinations for the standard regimen and for the CFZ-containing regimen against a variety
of MAC strains in BMDMs. BMDMs were infected with each MAC strain and treated with the drug regimen at 1 × MIC according to the data in Table 1. (A) M. avium
ATCC 700898 and M. intracellulare ATCC 13950, (B) M. avium SMC #1 and M. avium SMC #7 and (C) M. intracellulare SMC #8 and M. intracellulare SMC #11
were assessed at 72 h post-infection by plating serially diluted cell lysates on 7H10-OADC agar plates. Each experiment was repeated at least twice independently
with triplicate wells; the results of a representative experiment are shown. The Mann–Whitney test was used to evaluate significance, and the results are represented
as the mean value ± S.D. ***p < 0.001 and n.s., not significant. CTL, untreated control; CLR-EMB-RIF, standard regimen; CLR-EMB-CFZ, CFZ-containing regimen;
hpi, h post-infection.
post-infection, the treatment efficacies of the regimen containing
CFZ instead of RIF and the standard regimen were investigated
for 2 and 4 weeks (Figure 4A). The impact of the CFZ-containing
regimen on bacterial load is shown as the mean and log10
reduction in CFU. At both 2 and 4 weeks post-treatment, there
was a significant reduction in the numbers of M. avium SMC
#7 in the CFZ-containing regimen group, with a reduction of
2.24 log10 units at 2 weeks and 2.10 log10 units at 4 weeks
compared with those in the standard regimen group (p < 0.001).
Interestingly, the bacterial load of the CFZ-containing regimen
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FIGURE 4 | Comparative assessment of treatment efficacy of the standard and CFZ-containing regimens in a murine model of chronic progressive MAC-PI.
(A) Schematic design of the in vivo experiment. BALB/c mice were infected with the M. avium SMC #7 clinical isolate via aerosolization, achieving a mean initial
bacterial number of 2 × 105 CFUs in the lungs. Two weeks and 4 weeks of therapy were initiated with the standard and CFZ-containing regimens at 8 weeks
post-infection. The daily drug doses were 100 mg/kg for CLR and EMB, 10 mg/kg for RIF and 20 mg/kg for CFZ. The mice were euthanized, and the lungs were
homogenized for histopathological examination and bacterial counts at 2 and 4 weeks post-treatment. Plotted infection data and mean CFU counts and bar graphs
for the log10 reduction in CFU from treatment initiation in the (B) lungs, (C) spleens and (D) livers were assessed after 2 and 4 weeks of treatment with the two
regimens by plating serially diluted tissue lysates onto 7H10-OADC agar plates. The broken vertical line of each plotted data indicates the day of treatment initiation.
The statistical significance in (B–D) was calculated by one-way ANOVA followed by Tukey’s multiple comparison test, and the results are represented as the mean
value ± S.D. **p < 0.01, ***p < 0.001 and n.s., not significant. MAC-PI, M. avium complex-pulmonary infection; CTL, untreated control; CLR-EMB-RIF, standard
regimen; CLR-EMB-CFZ, CFZ-containing regimen.
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group at 2 weeks was reduced effectively compared with that
of the standard regimen group at 4 weeks, with a 1.04 log10
reduction (p < 0.05) (Figure 4B). In the spleen and liver, the
antibiotic activities were similar, with a reduction in activity in
the lung (Figures 4C,D). In the spleen, reductions of 1.68 log10
units at 2 weeks and 2.45 log10 units at 4 weeks were obtained for
the CFZ-containing regimen group compared with the standard
regimen group (p < 0.001). In the liver, reductions of 1.97 log10
units at 2 weeks (p < 0.001) and 1.16 log10 units at 4 weeks
(p < 0.01) were obtained in the CFZ-containing regimen group
compared with the standard regimen group.
Histopathological staining showed inflamed areas in
M. avium-infected lungs (Figure 5A), consistent with the
bacterial loads. Surprisingly, the inflamed area was diminished
by the CFZ-containing regimen at only 2 weeks after starting
treatment (p < 0.001) and was reduced even more than at
treatment initiation (p < 0.001), but there was no significant
difference in lung gross pathologic findings between the
untreated control group and standard regimen group. At 4 weeks
post-treatment, both the standard regimen group and CFZ-
containing regimen group had significantly reduced inflamed
areas (p < 0.001), and treatment with the CFZ-containing
regimen resulted in more antibacterial activity than treatment
with the standard regimen (p < 0.01) (Figure 5B).
DISCUSSION
Although previous studies showed that a treatment regimen
containing CFZ resulted in favorable outcomes for patients with
MAC-PD, there have been few studies elucidating its effect on
macrophages and relevant animal models. In the present study,
CFZ showed effective intracellular anti-MAC activity against
all MAC strains, and the CFZ-containing regimen provided
significantly improved treatment efficacy in a murine model of
chronic progressive MAC-PI, with greater efficacy after 2 weeks
of treatment with this regimen than after 4 weeks of treatment
with the standard regimen, by rapidly reducing bacterial loads
and lung inflammation. Recently, due to a lack of compatible new
drugs with low toxicity and high effectiveness, existing drugs have
been repurposed or repositioned as the current candidate drugs
for the treatment of MAC disease (Wu et al., 2018).
Macrolides have been considered the cornerstone drugs in the
treatment of MAC disease, followed by EMB and RIF (Daley
et al., 2020). Kim et al. (2019) reported that MAC-PD patients
who maintained treatment with either EMB or RIF with a
macrolide had a higher probability of culture conversion than
patients who maintained treatment with a macrolide only, but
maintenance with EMB was superior to maintenance with RIF
in terms of treatment outcomes and microbiological cure rates.
In addition, Miwa et al. (2014) reported that a double regimen
without RIF was not inferior to a standard regimen with respect
to culture conversion after 12 months of treatment in patients
with MAC. Additionally, clinical research regarding the CFZ-
containing regimen and RIF-containing regimen demonstrated
that 100% of patients treated with CFZ achieved negative culture
results, while only 71% of patients treated with RIF had successful
sputum culture conversion (Jarand et al., 2016). For this reason,
we investigated the individual efficacy of first-line antibiotics
through intracellular activity in MAC-infected BMDMs. The
main limitation of in vitro DST is that fixed breakpoints of EMB
and RIF have not been clearly established, although those drugs
have been considered first-line drugs (CLSI, 2018). Therefore,
we attempted to evaluate the intracellular anti-MAC activities
of these drugs prior to conducting in vivo efficacy testing since
in vitro DST results varied according to MAC strains. To evaluate
the intracellular efficacies of antibiotics, seven different MAC
strains showing different MIC values against antibiotics were
used. Intriguingly, RIF did not confer anti-MAC activity in
BMDMs despite its low MIC, regardless of the macrophage
source (i.e., different mouse strains). Surprisingly, few studies
have investigated the intracellular activity of RIF against MAC
infection in macrophages. Moreover, no consistent results among
studies have been reported; Rastogi et al. (1987) and Rastogi and
Labrousse (1991) showed that RIF was bactericidal for M. avium
in the J774 mouse macrophage cell line, whereas Yajko et al.
(1989) reported that 11 of 13 MAC strains survived in the same
J774 cells (with more than 90% of the initial number in infected
cells) after treatment with 8 mg/L RIF for 7 days.
The in vitro activity of CFZ against the MAC is also still
controversial. Huang et al. (2018) reported CFZ MIC ranges from
1 to 4 mg/L for 83 clinical MAC isolates of M. avium, with
MICs ≤ 1 mg/L against the majority of M. intracellulare isolates.
In addition, Kwak et al. (2020) reported that the MICs of CFZ
for 133 MAC strains ranged from 0.031 to 8 mg/L, and more
than 75% of the MAC isolates had MIC values ≤ 1 mg/L. The
cut-off values of several studies could be variable due to the use
of different MAC species and different culture conditions. In
our study, a total of seven MAC strains had MIC values from
1 to 4 mg/L, consistent with the range reported for CFZ in
previous studies (Huang et al., 2018; Kwak et al., 2020). Since
drug options have been limited for MAC-PD treatment, the
general choice of drug regimen has been empirically selected
based on MIC determination (Renvoise et al., 2014). However,
unexpectedly, RIF showed the weakest correlation between its
in vitro MIC and intracellular anti-MAC activity. In contrast,
in our investigation, CFZ could be an effective drug displaying
positive correlations between the in vitro MIC and intracellular
anti-MAC activity, similar to CLR. In addition, CFZ had better
synergistic effects with CLR than with RIF on growth inhibition
of all strains except M. avium SMC #7 in macrophages. Indeed,
many previous studies have reported variation in virulence
among MAC strains and different host responses in macrophages
and mice (Amaral et al., 2011; Agdestein et al., 2014; Bruffaerts
et al., 2017; Abdissa et al., 2018; Rindi et al., 2018; Kannan et al.,
2019). Moreover, antibiotics are well known to be associated
with immune responses (Labro and Abdelghaffar, 2001; Tamaoki,
2004; Yuhas et al., 2007; Yuhas et al., 2011; Singh et al.,
2014). Hence, variation in virulence and host responses and the
influence of antibiotics might explain why intracellular M. avium
SMC #7 was inhibited by both regimens with the same efficacy.
Therefore, to evaluate the efficacies of the regimens for chronic
progressive disease, mice were infected via aerosol infection
with a variety of MAC strains including M. avium ATCC
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FIGURE 5 | Histopathological evaluation of lung inflammation between the standard and CFZ-containing regimens at 2 and 4 weeks post-treatment.
(A) Representative 10× and 100× magnification photomicrographs of H&E-stained lung tissue from the superior lobe of the right lung are shown. Each treatment
regimen is indicated below the representative lung pathology. (B) Quantitation of inflamed areas of the H&E-stained samples of (A) is presented as bar graphs. All
data for inflamed areas were analyzed by one-way ANOVA followed by Tukey’s multiple comparison test to evaluate significance, and the results are represented as
the mean value ± S.D. **p < 0.01, ***p < 0.001 and n.s., not significant. Pre-Tx, pre-treatment; CTL, untreated control; CLR-EMB-RIF, standard regimen;
CLR-EMB-CFZ, CFZ-containing regimen.
700898 and M. avium SMC #7. However, mice infected with
various MAC strains and M. avium ATCC 700898 underwent
bacterial clearance, and chronic progressive infection could not
be established (data not shown), whereas mice infected with
M. avium SMC #7 established a chronic pulmonary infection
with granulomatous inflammation. Although we found that the
CFZ-containing regimen was superior to the standard regimen
through the in vivo study with M. avium SMC #7, the intracellular
activity of CFZ-containing regimen displayed a lesser extent to
the other MAC strains in BMDMs. We assume that the difference
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in results between intracellular activity of CFZ and its in vivo
efficacy testing against M. avium SM #7 might be from the
frequencies of treatment and immune status between BMDMs
and animals. Thus, the refined intracellular drug assays that
mimic in vivo conditions should ensure more accurate results,
particularly, when testing new drugs. Nevertheless, our results
clearly displayed the effective intracellular activity of CFZ against
various clinical MAC strains in BMDMs.
Since effective MAC-PD treatment requires at least 12 months
of combination therapy (Daley et al., 2020) and since disease
progression may worsen radiologically due to severe lung
inflammation (Thomson and Yew, 2009), evaluating lung
inflammation during antibiotic treatment is necessary to devise
more effective MAC-PD chemotherapy regimens. Accordingly,
we showed that lung inflammation and bacterial loads declined
much earlier in mice treated with the CFZ-containing regimen
than in mice treated with the standard regimen. Lung
inflammation in mice treated with the CFZ-containing regimen
was significantly reduced at 2 weeks post-treatment, whereas lung
inflammation in mice treated with the standard regimen was not
significantly reduced at this time point. Moreover, treatment with
a CFZ-containing regimen at 2 weeks post-treatment was more
effective than treatment with a standard regimen for 4 weeks,
indicating that the CFZ-containing regimen also had a treatment-
shortening effect.
Overall, we evaluated a CFZ-containing regimen for the
treatment of a murine model of chronic progressive MAC-PI
based on its intracellular activity against a variety of MAC strains
in BMDMs. These results provide a rationale for the use of CFZ
as a component of an optimal treatment regimen instead of the
currently used standard regimen. Furthermore, investigations of
treatment regimens combining macrolides and CFZ with other
drugs to enhance treatment success in a short duration are
needed. Another important finding is that RIF generally had
no intracellular anti-MAC activity despite its low MICs against
MAC strains, indicating that the host-mediated mechanism of
RIF tolerance in macrophages is worth further investigation.
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